Free tool
FAERS Monitor: Abraxane
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021660 or its brand name (Abraxane, Paclitaxel). Reports on generic versions are filed under their own applications.
Reports
101,114
Serious
97,345
96% of reports
Hospitalization
41,399
Death reported
16,524
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea5,613
- neutropenia5,563
- off label use5,388
- diarrhoea5,265
- dyspnoea5,190
- anaemia4,891
- death4,509
- malignant neoplasm progression4,508
- fatigue4,309
- neuropathy peripheral4,095
- pyrexia3,984
- disease progression3,938
- vomiting3,898
- myelosuppression3,829
- febrile neutropenia3,772
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 626 |
| 2005 | 853 |
| 2006 | 665 |
| 2007 | 687 |
| 2008 | 946 |
| 2009 | 1,096 |
| 2010 | 1,148 |
| 2011 | 1,956 |
| 2012 | 2,607 |
| 2013 | 2,742 |
| 2014 | 2,623 |
| 2015 | 3,931 |
| 2016 | 4,464 |
| 2017 | 4,527 |
| 2018 | 6,481 |
| 2019 | 6,495 |
| 2020 | 6,372 |
| 2021 | 6,872 |
| 2022 | 8,471 |
| 2023 | 8,823 |
| 2024 | 10,274 |
| 2025 | 10,694 |
| 2026 | 7,760 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,953,045 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 3,829 | 24.6 | 23.8 | 77,672 |
| febrile neutropeniaSignal | 3,772 | 12.5 | 12.1 | 37,680 |
| malignant neoplasm progressionSignal | 4,508 | 9.5 | 9.3 | 33,065 |
| neuropathy peripheralSignal | 4,095 | 9.3 | 9.0 | 29,200 |
| neutropeniaSignal | 5,563 | 8.8 | 8.6 | 37,284 |
| disease progressionSignal | 3,938 | 7.1 | 6.9 | 20,159 |
| anaemiaSignal | 4,891 | 5.4 | 5.3 | 17,462 |
| pyrexiaSignal | 3,984 | 2.4 | 2.3 | 3,306 |
| dyspnoea | 5,190 | 1.9 | 1.9 | 2,311 |
| vomiting | 3,898 | 1.7 | 1.7 | 1,219 |
| diarrhoea | 5,265 | 1.7 | 1.7 | 1,560 |
| nausea | 5,613 | 1.5 | 1.4 | 897 |
| off label use | 5,388 | 1.3 | 1.2 | 346 |
| fatigue | 4,309 | 1.2 | 1.1 | 89 |
| death | 4,509 | 1.1 | 1.1 | 34 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.